In Parkinson's disease (PD), conformational changes in the α-synuclein monomer precede the formation of Lewy bodies. We examined postmortem PD and undiseased (control) substantia nigra for evidence of pathological crosslinking of α-synuclein by tissue transglutaminase (tTG) using immunohistochemistry, immunoprecipitation, and Western blot. Consistent with previous reports, we found that both tTG and its substrate-characteristic N ε -(γ-glutamyl)-lysine crosslink are increased in PD nigral dopamine neurons. Furthermore, both the tTG protein and its substrate crosslink coprecipitated with α-synuclein in extracts of PD substantia nigra. Unexpectedly, the isodipeptide crosslink was detected in the α-synuclein monomer as well as in higher molecular mass oligomers of α-synuclein. Although the intramolecularly crosslinked α-synuclein monomer was present in control tissue, it was highly enriched in PD substantia nigra. Conversely, significantly less uncrosslinked α-synuclein remained in the postimmunoprecipitate lysate of PD tissue than in control. Crosslinked α-synuclein, formed at the expense of the total α-synuclein monomer, correlated with disease progression. These results demonstrate that much of the α-synuclein monomer in PD nigra is crosslinked by tTG and thus may be functionally impaired. This modification appears to be an early step in PD pathogenesis, preceding the aggregation of α-synuclein in Lewy bodies.
data contribute to an increasing body of evidence that modification of the α-synuclein molecule is an early event in protein aggregation and PD pathogenesis (7) (8) (9) .
The enzyme tissue transglutaminase (tTG), which catalyses covalent crosslinking between reactive lysine and glutamine residues, is a likely candidate for mediating the formation of the protein polymers comprising the inclusions found in PD and other neurodegenerative diseases. Substrates of tTG include β-amyloid, tau, Huntingtin, and the NAC fragment of α-synuclein, all of which are proteins that aggregate in various neurodegenerative diseases (10) (11) (12) (13) . Increased levels of tTG and its substrate-characteristic N ε -(γ-glutamyl)-lysine crosslink have been identified in the SNpc of postmortem Parkinson brain, and tTG was found to be colocalized with α-synuclein in Lewy bodies (14, 15) . In addition, tTG has been shown to stimulate α-synuclein aggregation in an α-synuclein-overexpressing COS 7 cell line (15) .
In the present study, we investigated whether tTG-induced crosslinking is a factor in the modification and aggregation of α-synuclein in the degenerative SNpc in PD. We now confirm that α-synuclein is a substrate of tTG in the human SNpc and that the crosslinking of this protein is greatly increased in PD brain. Unexpectedly, we identified a novel isoform of the α-synuclein monomer that is intramolecularly crosslinked by tTG. The crosslinked monomer is especially abundant in the SNpc of PD patients. These data offer insight into the initial modification steps of the α-synuclein molecule in PD brain.
METHODS

Brain samples
Parkinson cases (2 females, 4 males; Hoehn and Yahr stages 3-5) and control cases (1 female, 3 males) were obtained from the University of Miami Brain Endowment Bank and the UCLA National Neurological Research Specimen Bank (Table 1) . Control brain tissue was obtained from individuals whose previous medical histories included no record of neurological or psychiatric disease. The clinical and neuropathological diagnoses of PD were made according to published criteria (16) (17) (18) . The motor symptoms were dominated either by tremor or rigidity in combination with hypokinesia. At neuropathological examination, SNpc dopamine neurons were identified by the intracellular presence of neuromelanin, a catecholamine-specific pigment that is found in >80% of dopamine neurons in SNpc (19) but not in nondopaminergic neurons. Hence, neuromelanin-containing neurons of SNpc can be presumed to be dopaminergic since dopamine is the only catecholamine expressed in this nucleus. The SNpc of all six PD cases exhibited a marked reduction of neurons containing neuromelanin, neuromelanin incontinence, and increased astrogliosis. A substantial proportion of the surviving neuromelanin-laden neurons contained Lewy bodies and/or pale bodies. The brains of all of the control cases were free of PDrelated pathology (Table 1) . Human brain tissue was harvested 6.5-16 h postmortem. The substantia nigra was dissected and rapidly frozen in isopentane cooled on dry ice.
Tissue fractionation
Nigral tissue frozen and stored at -70°C was partially thawed to -20°C. Samples were dissected and homogenized by sonication at 4°C in 1:10 (g:vol) TBS buffer (50 mM Tris-HCl, 175 mM NaCl, pH 7.4) containing protease inhibitors (protease inhibitor cocktail, Sigma, St. Louis, MO), 2 mM phenyl-methyl-sulfonyl-fluoride (PMSF, Sigma), and 5 mM ethylene-diamine-tetraacetate (EDTA, Sigma). Samples were centrifuged at 1000 g for 5 min at 4°C to remove white matter. The resultant whole tissue lysate was used to detect tTG expression. To assess differences in solubility of various α-synuclein species contained in the tissue, the following fractionation procedures were performed. Whole tissue lysate was centrifuged at 35,000 g for 60 min at 4°C. The supernatant, termed the TBS-soluble (S1) fraction, contained all cytoplasmicsoluble proteins. All of the following procedures were performed at room temperature. The remaining pellet was washed twice with TBS, resuspended, sonicated in TBS buffer containing 5% sodium dodecylsulfate (SDS, Quality Biological, Inc., Gaithersburg, MD) and then centrifuged at 35,000 g for 30 min. The supernatant from this centrifugation, the SDS-soluble (S2) fraction, contained the membrane-associated proteins. The resultant pellet was washed twice with 5% SDS buffer and extracted in 8 M urea (Fisher Scientific, Fair Lawn, NJ)/8% SDS. This fraction was termed the urea-soluble (P) fraction. The efficacy of the fractionation procedure was assessed by analyzing the expression of the membrane-associated protein Annexin II in the three fractions.
Western blot
Protein concentrations were analyzed using the Lowry assay. Aliquots containing 10 µg of protein were dissolved in equal volumes of 2x SDS sample buffer, boiled for 5 min, and loaded onto 4-20% linear gradient polyacrylamide gels (Invitrogen, Carlsbad, CA). Proteins were separated by electrophoresis using 120 V constant applied voltage for 90 min and then transferred onto a polyvinylidene flouride (PVDF) membrane (Invitrogen) by the application of 25 V for 1.5 h. For immunodetection of α-synuclein, tTG, isodipeptide crosslinked proteins, Annexin II, and β-actin, membranes were incubated overnight at 4°C with Synuclein-1 (Syn-1), an α-synuclein-specific mouse monoclonal antibody (mAb, 1:500, BD Transduction Laboratories, Lexington, KY); tTG3, a tissue transglutaminase mouse mAb (1:500, Neomarkers Inc., Fremont, CA); a mouse anti-isodipeptide mAb (Covalab, Lyon Sud, France, 1:2000), a mouse mAb to Annexin II (1:2000, Transduction Laboratories), and a mouse mAb to β-actin (1:2000, Sigma), respectively.
After being rinsed and incubated with HPR-coupled secondary goat anti-mouse antibody (1:2000, BD Transduction Laboratories), the reactive bands were visualized using chemiluminescence (ECL, Amersham, IL). In several experiments, the membranes were stripped and reprobed with the β-actin mAb, as a control for protein extraction efficiency and potential variability in sample loading. The molecular masses of α-synuclein and tTG proteins were estimated by comparing migration levels of the immunoreactive bands with those of the standard marker See-Blue (Invitrogen).
Immunohistochemistry
A portion of each substantia nigra was immersion fixed in 4% paraformaldehyde (Fisher Scientific) in phosphate buffered saline (PBS, Digene, Beltsville, MD) for 12 h, dehydrated in 20% sucrose (ICN Biomedicals Inc., Aurora, OH) in PBS, and rapidly refrozen. Serial coronal sections (30 µm) through the substantia nigra were cut with a cryostat.
Sections processed for single labeling tTG and N ε -(γ-glutamyl)-lysine isodipeptide immunohistochemistry were incubated free-floating for 3 days at 4°C in 0.01 M PBS containing tTG3 (1:4000), or the mouse anti-isodipeptide mAb, 1% normal horse serum (Vector Laboratories, Burlingame, CA), and 0.3% Triton X-100 (Sigma). The products of the antibody immunoreactions were then developed according to the avidin biotin complex (ABC) method with the Vectastain elite ABC kit (Vector Laboratories). Vector blue was used as a chromogen to allow a clear distinction between the brown neuromelanin pigment and the immunostaining.
For fluorescent double labeling, the tTG3 and isodipeptide antibodies were used in combination with a rabbit anti-α-synuclein polyclonal antibody (pAb, Chemicon International; Temecula, CA, 1:500). The staining procedure was performed as described above. Rhodamine was used to detect tTG and isodipeptide crosslinks, and fluorescein isothiocyanate (FITC) was used to detect α-synuclein. Detection of specific fluorescent labeling is complicated by the autofluorescence produced by neuromelanin in the dopaminergic cells of the SNpc. To mitigate this confounding factor, sections were incubated with 0.1 M phosphate buffer (pH 7.4) containing 0.25% potassium permanganate for 10 min, followed by thorough washes in PBS, before the immunolabeling procedure. This procedure has been shown to successfully abolish the autofluorescence (20) . After chromogen deposition, sections were mounted on gelatin-coated slides.
Representative sections were used for negative tissue controls by processing them for immunoreactivity with the following alterations of procedure: 1) omission of the primary antibody, 2) omission of the secondary antibody, and 3) substitution of the primary antibody with normal mouse IgG or rabbit IgG.
Immunoprecipitation
Immunoaffinity purification of proteins containing transglutaminase-induced isodipeptide crosslinks was performed using an excess of Sepharose beads prebound to the anti-isodipeptide 81D4 mAb according to a protocol developed by CovalAb, as described previously (13) . In brief, 50 µl Sepharose beads prebound to 81D4 mAb were washed in 1.0 ml of TBS (10 mM Tris-HCl, 0.14 M NaCl, pH 7.5) with 0.1% Tween-20 (Sigma) and were gently shaken for15 min. This mixture was centrifuged at 6000 g for 10 s at room temperature; the supernatant was discarded and washed again. Next, 500 µg of protein lysate (1 mg/ml) was added to an Eppendorf tube containing the washed Sepharose-81D4 beads and the mixture was incubated for 1 h at 37°C. The incubated lysate was centrifuged at 2000 g for 2 min at room temperature. The resultant supernatant was discarded, and the pellet was washed in 1.0 ml TBS with 0.1% Tween 20 with gentle shaking for 15 min and then centrifuged at 3000 g for 2 min. The supernatant was discarded, and the pellet was washed three times as before. Then, 50 µl of loading buffer (50 mM Tris-HCl, pH 6.8, 5% β-mercaptoethanol, 0.2% SDS, 0.1% bromophenol blue, 10% glycerol) were added to the washed pellet. The sample was mixed by vortex, next placed in a 90°C water bath for 5 min, and then mixed by vortex again. The antigen was separated from the Sepharose beads by centrifugation at 10,000 g for 2 min at room temperature. The resultant supernatant contained the glutamyl-lysine crosslinked proteins. Crosslinked α-synuclein was detected by Western blot of the immunoprecipitation lysate. Residual uncrosslinked α-synuclein was detected by Western blot of the postimmunoprecipitation lysate; that is, the lysate remaining after isodipeptide-containing proteins had been extracted. The Syn-1 mAb against α-synuclein was used as the primary antibody in both procedures.
For immunoprecipitation of α-synuclein, 10 µl of α-synuclein mouse mAb (syn-211, Zymed Laboratories, San Francisco, CA) was bound to 20 µl of antimouse IgG Sepharose beads solution (Sigma) by incubation at room temperature for 2 h. Then, the mixture was centrifuged at 6000 g for 10 s at room temperature, the supernatant was discarded, and the pellet was washed as before. Next, 200 µg of protein lysate (1 mg/ ml) were added, and the immunoprecipitation procedure was performed as described above. Western blotting was performed on the final immunoprecipitation lysate, using procedures described above. Membranes were probed either with the isodipeptide mAb, to confirm the detection of crosslinked α-synuclein species, or with the tTG3 mAb, to detect molecular interaction between tTG and α-synuclein.
Data analysis and statistics
For the Western blot and immunoprecipitation data, the image of each band was scanned with a densitometer (GS-700; Bio-Rad). Bands were analyzed by densitometry using the UN-SCAN-IT gel Version 5.1 program for Windows (Silk Scientific, Orem, UT). In some PD and control cases, insufficient tissue was available to perform all experiments, thus accounting for the reduction of sample size in some experiments.
Comparisons of Western blot data from the control and PD groups were assessed using the twosample, unpaired t test (two-tailed). Additionally, linear regression analysis was performed to detect correlations between protein concentrations and disease progression. The Pearson correlation test was used to identify significant correlations. A two-tailed P value for all tests was set at the 0.05 level for statistical significance.
RESULTS
Two tTG-immunoreactive proteins with molecular masses of ~78 and 55 kDa were extracted from SNpc lysate and detected by Western blot. The migration characteristics of these proteins indicate that they are the whole tTG molecule and a splice variant lacking the C-terminal GTP binding domain, respectively (21, 22) . Expression of the 78 kDa molecule was significantly increased in PD nigra (t=3.92; P<0.05). The more variable increase in expression of the 55 kDa splice variant in PD nigra did not reach statistical significance (Fig. 1 ).
The expression of tTG in substantia nigra tissue was examined also by immunohistochemistry. Labeling of the tTG protein revealed low-level expression in dopamine neurons of SNpc of the control cases ( Fig. 2A ). In the PD cases, by contrast, cellular expression of tTG in dopamine neurons of SNpc was much stronger (Fig. 2B ). Although some tTG immunoreactivity was observed within Lewy bodies in the PD tissue, the expression was sporadic and weak ( Fig. 2C) . Fluorescent double labeling of tTG and α-synuclein also revealed colocalization in cell bodies of almost all dopamine neurons in the PD cases (Fig. 3A , B, C), while colocalization of these proteins was rare in control cases (Fig. 3D, E, F) . Thus, the double-labeling experiments confirmed and extended the findings of the single-label study, revealing that tTG expression was increased in PD nigra and frequently colocalized with α-synuclein in dopamine neurons, although typically not within the Lewy bodies per se (Fig. 3A, B 
, C).
Consistent with increased tTG expression, the N ε -(γ-glutamyl)-lysine isodipeptide crosslink also was markedly increased in the nigral dopamine neurons of PD cases, as compared with control cases. In contrast with the sparse antibody labeling of the tTG protein in Lewy bodies, there was intense labeling of the N ε -(γ-glutamyl)-lysine isodipeptide crosslink in these inclusions (Fig. 4A , B, C). Immunofluorescent double labeling confirmed the colocalization of α-synuclein and isodipeptide crosslinks in somata and in Lewy bodies in the majority of nigral dopamine neurons (Fig. 5A, B, C) .
The solubility and degree of polymerization of the α-synuclein molecule in nigral tissue were assessed in PD and control cases by subcellular fractionation followed by Western blot. Aqueous-soluble, that is, hydrophilic cytoplasmic proteins, were collected in the Tris buffersoluble (S1; Fig. 6A ) fraction. Detergent-soluble, that is, hydrophobic membrane-associated proteins, were extracted in the SDS-soluble (S2; Fig. 6B ) fraction. Highly hydrophobic proteins and protein aggregates from the resultant pellet (P; Fig. 6C ) fraction were extracted in 8 M urea/8 M SDS. The efficacy of the fractionation procedure was assessed by the relative concentrations of Annexin II, a marker of plasma membrane and early endosomes (23) . Annexin II was highly concentrated in the S2 membrane soluble fraction but weak in the cytosolic S1 fraction and absent from the P fraction (Fig. 6D) . In both PD and control tissue samples, an α-synuclein-reactive band migrating at ~16 kDa was detected in the S1 fraction, indicating the presence of the α-synuclein monomer in cytoplasm (Fig. 6A) . The concentration of the soluble monomer was significantly reduced in the PD samples (t=2.14; P<0.05) and inversely correlated with disease progression (R 2 =0.476; P<0.05; Fig. 7 ). The α-synuclein monomer was detected also in the S2 fraction in both PD and control samples, indicating its association with membrane (Fig. 6B ). In contrast with the S1 fraction, the S2 fraction of the PD samples did not have lower concentration of the α-synuclein monomer. Instead, there was ~30% more lipid-associated α-synuclein monomer in the PD samples than in controls, a difference that approached statistical significance (t=2.14; P=0.06). Furthermore, in the S2 fractions of the PD, but not the control samples, additional α-synuclein-immunoreactive bands were observed at migration levels of ~32, 36, and 45 kDa, indicating the presence of small membrane-associated oligomers (Fig. 6B) . α-Synuclein-containing protein from the insoluble P fraction of PD, but not control samples, was observed in the stacking gel (Fig. 6C) . The α-synuclein detected in these bands is a high molecular mass, hydrophobic protein aggregate that is likely to be whole or fragmental Lewy bodies.
To determine whether the nigral α-synuclein contained the tTG-characteristic crosslink, comigration of α-synuclein species with isodipeptide crosslink-containing proteins was examined in PD and control whole lysate. After electrophoresis, single lanes were split and immunolabeled with the Syn-1 mAb or the isodipeptide mAb (Fig. 8A) . In both control and PD lysate, a prominent isodipeptide-reactive band of ~52 kDa that has been described previously (14) was observed. In addition, bands were detected at ~16, 32, and 45 kDa. These bands were all markedly stronger in the PD tissue as compared with control tissue. An α-synuclein-reactive band identifying protein extracted from PD, and to a lesser extent, control lysate, comigrated at 16 kDa, suggesting that the α-synuclein monomer contained the isodipeptide crosslink. Moreover, α-synuclein reactive bands were observed at ~32 and 45 kDa in PD but not control nigra. The finding of isodipeptide crosslinking in the higher molecular mass α-synuclein-positive species indicates the presence of oligomers containing at least one α-synuclein molecule and the tTG crosslink. The appearance of α-synuclein-positive oligomers with apparent molecular masses of 32 and 45 kDa is suggestive, although not conclusive, that these bands identify the homodimer and homotrimer of α-synuclein.
As a control procedure, membranes were stripped and reprobed with the mAb against β-actin, a cellular constituent protein that remains unchanged in its relative proportion in PD. There was no difference between the concentration of β-actin extracted from PD and control nigral tissue, indicating both the consistency of protein extractability between PD and control tissue and the accuracy of the amounts of protein loaded per sample (Fig. 8B) .
To confirm the presence of isodipeptide crosslinked α-synuclein in the PD nigra, crosslinked proteins were immunoprecipitated from the S1 fraction, using the mAb selective for the N ε -(γ-glutamyl)-lysine isodipeptide crosslink prebound to Sepharose beads (Fig. 9) . A strong α-synuclein-positive band migrating at 16 kDa was detected in all PD samples, indicating the presence of the tTG-characteristic isodipeptide crosslink in the soluble α-synuclein monomer. A significantly lower concentration of the crosslinked α-synuclein monomer was eluted from the control nigra (t=7.59; P<0.001; Fig. 9A ). With longer chemiluminescence exposure time, α-synuclein oligomers containing the tTG crosslink were detected in PD, but not control, samples at ~36, 49, and 64 kDa (Fig. 9B) . As a control procedure, the primary antibody was omitted, in which case only the band corresponding to the isodipeptide antibody IgG was detected (Fig. 9C) . Examination of the postimmunoprecipitation lysate by Western blot revealed that the concentration of uncrosslinked α-synuclein monomer remaining in PD nigra after the extraction of the crosslinked proteins was significantly less than in control tissue (t=2.53; P<0.05; Fig. 9D ). There was a strong positive correlation between the degree of PD progression and the concentration of the crosslinked soluble α-synuclein monomer extracted from the S1 (R 2 =0.932; P<0.01; Fig. 10 ).
To verify the presence of crosslinked α-synuclein in nigral tissue by independent means, the reciprocal experiment was performed, i.e., α-synuclein proteins from the S1 lysate were immunoprecipitated by the Syn-211 antibody. After immunoprecipitation, the isodipeptide crosslinked proteins were detected by Western blot using the 81D4 mAb. In control tissue, a weak band appeared at 16 kDa, at the same position that the α-synuclein monomer was detected by Syn-1, and this band was strongly enhanced in PD tissue. These results are completely consistent with those obtained by isodipeptide immunoprecipitation. The prominent band at ~52 kDa was detected in both control and PD tissue. Additionally, a band was detected at ~32 kDa that was highly enriched in the PD tissue. Immunoreactivity was also detected at ~45 kDa, but given the extremely high concentration of the protein that has been identified as being of a molecular mass of ~52 kDa (14) and the extensive spatial range of its immunoreactivity, a 45 kDa band could not be discretely identified. Higher molecular mass bands were also observed at ~80, 98, and 116 kDa, which for unknown reasons were slightly more prominent in control than in PD tissue (Fig. 11A, B) . The immunoprecipitation assay is severely degraded by the use of detergent buffers, which are used to extract proteins of the S2 and P fractions; therefore, we were only able to immunoprecipitate proteins from the S1 fraction.
Despite the fact that the presence of crosslinked α-synuclein could not be examined directly by immunoprecipitation, Western blot analysis of proteins from the brain lysate fractions provided additional information. Proteins extracted from the three fractions of control and PD substantia nigra were probed with the anti-isodipeptide mAb. Several bands were evident, including the prominent band of ~52 kDa, which appeared in all three fractions. In addition, bands were detected at ~16, 32, and 45 kDa, consistent with those identified in both immunoprecipitation experiments. In contrast, however, all three of the latter bands were notably most prominent in the S2 fraction. Likewise, the putative α-synuclein proteins detected in the 16, 32, and 45 kDa bands were in greater concentration in the PD than in the control tissue in this fraction (Fig. 12) .
Although tTG is the most likely candidate to mediate α-synuclein crosslinking in PD, other transglutaminases also catalyze the N ε -(γ-glutamyl)-lysine crosslink. The identity of the transglutaminase colocalized with α-synuclein was directly tested by immunoprecipitation of α-synuclein from SNpc lysate using Syn-211, followed by immunoblotting with the tTG-specific antibody tTG3. The 78 kDa full-length tTG coprecipitated with α-synuclein from samples of PD, but not control, cases (Fig. 13A, B) .
DISCUSSION
The present results demonstrate that tTG expression is increased in the SNpc of PD patients and that the tTG-characteristic N ε -(γ-glutamyl)-lysine crosslink is extensive in nigral dopaminergic neurons and Lewy bodies. Both immunohistochemical colocalization and immunoprecipitation studies show that α-synuclein is a tTG substrate in human nigra and that crosslinked α-synuclein proteins are markedly enhanced in PD. The finding that the tTG signature crosslink, but not the tTG protein, is abundant in Lewy bodies suggests that most tTG-catalyzed protein crosslinking occurs in cytoplasm outside the Lewy bodies before incorporation of protein into these inclusions. The specific identification of the tissue-type isoform as the transglutaminase crosslinker for the α-synuclein substrate was confirmed by the coprecipitation of α-synuclein and the tTG protein, although this association was only detected in PD tissue. Binding of enzyme and substrate is transitory and thus more difficult to detect than the identification of the isodipeptide, which is a permanent feature of the substrate protein. Hence, given the low concentration of isopeptide crosslinked α-synuclein in control tissue, it is not surprising that the transient association between α-synuclein and tTG was not detected.
Unexpectedly, we identified a novel isoform of the soluble α-synuclein monomer that contained a tTG-catalyzed intramolecular crosslink. Crosslinking induced by tTG is typically associated with intermolecular covalent bonds creating a plexus of large numbers of molecules, a role that is important for wound healing and stabilization of tissues such as blood vessels (24) (25) (26) . Intramolecular crosslinking is rare, and only a few examples have been reported (27) .
The procedure of immunoprecipitation is a process that concentrates proteins, as only the proteins binding to the bait antibody are extracted. This provides the explanation for the detection of the crosslinked α-synuclein in cytoplasm that might have gone unnoticed using the standard Western blot procedure. Despite the relatively low overall concentration of crosslinked α-synuclein in the cytoplasmic S1 fraction, it was highly enriched in PD tissue. This was especially true of the crosslinked α-synuclein monomer that was increased at the expense of the total concentration of the α-synuclein monomer in the S1 fraction. Additionally, the total expression of α-synuclein in the cytoplasmic S1 fraction was significantly lower in PD than in control cases. In contrast, both the total and crosslinked α-synuclein were increased in the (membrane-containing) S2 fraction in the PD subjects as compared with controls. Even though the concentration of crosslinked α-synuclein appears to be greater in the membrane-associated fraction than in the cytoplasmic fraction, we propose that the crosslinking is initiated at the site of the cytoplasmic-soluble monomer for the following reasons. First, a depletion of noncrosslinked, normal α-synuclein monomer and a concomitant increase in the concentration in the S1 fraction of the tTG-crosslinked monomer both correlated with disease progression. This finding is consistent with a net equilibrium shift from cytoplasm to membrane. Second, it has been recently discovered that ~90% of all α-synuclein in Lewy bodies is phosphorylated at Ser 129, yet the steady-state physiological phosphorylation of this residue is only 4% (28) . Phosphorylation of the Ser 129 residue in α-synuclein markedly reduces its lipid affinity and has been proposed to be the mechanism by which this protein translocates from membranes to cytoplasm (29) . Taken together, these data provide strong evidence that cytoplasmic phospho-ser α-synuclein is the initial locus for tTG-induced crosslinking. We propose that the tTG-induced intramolecular crosslinking of the soluble α-synuclein monomer is a crucial early step in this process.
The higher concentration of crosslinked protein comigrating with α-synuclein in the S2 fraction implies that crosslinking induces a solubility change that promotes a shift to a membrane compartment. It is important to note that α-synuclein aggregation based on the hypothesized change in solubility of the crosslinked monomer would not alter the serine phosphorylation state of the protein, since its pathological membrane association is not related to the dephosphorylation preceding its normal functional translocation to membrane. Independent labs have shown that membranes can become nucleation sites for α-synuclein aggregation (30, 31, 32) .
In sum, the current data support our hypothesis that intramolecular crosslinking of the cytoplasmic soluble phospho-ser α-synuclein monomer is initially catalyzed by tTG. We propose that this step is accompanied by a change in lipid solubility and a subsequent association with intracytoplasmic membranes, such as vesicles, which provide nucleation sites. Our hypothesis of the normal role of α-synuclein in vesicle recycling and its perturbation in early PD pathogenesis is illustrated schematically in Fig. 14. A direct examination of the relationship between the soluble and membrane-associated tTG-crosslinked proteins remains an important goal.
Despite the fact that proteins of the P fraction could not be immunoprecipitated, our immunohistochemical data showing abundant isodipeptide crosslinks in Lewy bodies suggest that the insoluble α-synuclein aggregates of the P fraction contain tTG-crosslinked protein. The aggregation of α-synuclein and other proteins into the large and extensively crosslinked Lewy bodies is hypothesized to be a relatively late development in PD pathogenesis.
The present data offer at least two possible bases for α-synuclein-associated pathology in PD. Our findings indicate that despite almost normal levels of the total soluble α-synuclein monomer in PD nigra, the amount of the uncrosslinked, presumably functional, α-synuclein was significantly reduced. In previous work, we determined that α-synuclein translocates between plasma membrane and cytosol in response to cholinergic stimulation and appears to participate in muscarinic receptor endocytosis (33) . This finding, together with results from other laboratories (34, 35) , led us to propose that this physiological translocation is accompanied by a conformational change in the α-synuclein molecule. The presence of an internal molecular crosslink can be predicted to impair the ability of α-synuclein to alter its configuration. The increase of the crosslinked α-synuclein monomer at the expense of the uncrosslinked normal isoform lends support to the hypothesis that hypofunctionality of α-synuclein is a factor in PD pathogenesis.
The second possibility is that the crosslinked monomer itself could be directly toxic or it could induce toxicity indirectly by providing a nucleation site for α-synuclein aggregation. The appearance of relatively small oligomers containing the α-synuclein crosslink suggests that the aggregation of α-synuclein into insoluble inclusions may be seeded by the crosslinked monomer and progress in size through the formation of small oligomers. As such, aggregates become larger and more insoluble, and they may contribute to neurotoxicity by saturating cellular machinery, such as proteasome and lysosome. It is important to note that the proposed loss-offunction and gain-of-function hypotheses are not mutually exclusive and the complex pathogenesis of PD may include both mechanisms.
Although a small amount of α-synuclein crosslinking appears to occur in normal aging, the process is accelerated in PD. It remains to be determined what factors lead to the pathological crosslinking of α-synuclein by tTG. The protein tTG has a dual function as a G-protein coupled to α1B and 1D adrenergic receptors mediating phospholipase C-activated phosphatidylinositol production (36, 37) , as well as being a protein crosslinker. The G-protein function of tTG is activated by GTP and inhibited by calcium; conversely, the crosslinking activity of tTG is promoted by calcium and inhibited by GTP. Physiological levels of GTP normally prevent the aberrant activity of tTG in response to transient Ca 2+ currents. The 15-30% reduction in complex I activity of the electron transport chain that characterizes sporadic PD (38, 39) may contribute to a chronic reduction of ATP and GTP, which may promote the crosslinking activity of tTG. The elucidation of the entire cascade leading to aberrant tTG crosslinking of α-synuclein in PD may identify the earliest events in PD pathogenesis and point to novel targets for therapeutic interdiction.
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The University of Miami Brain Endowment Bank and the UCLA National Neurological Research Specimen Bank are acknowledged for generously supplying human midbrain tissue. This work was supported by the Fogarty International Center, the "Prinses Beatrix" Foundation, a grant from the NPF, and a donation by the J. Bradford Sympson charitable trust fund. band, corresponding to the whole tTG molecule and a splice variant respectively, was detected using the tTG3 mAb. Numbers beneath PVDF membrane correspond to C and PD cases identified in Table 1 . Synuclein monomer was expressed in S1 fraction (aqueous soluble, hydrophilic fraction) of both control and PD substantia nigra. B) Multiple α-synuclein species in S2 fraction (detergent soluble, hydrophobic fraction) were present in the PD but not the control lysate. C) Expression of a high molecular weight, α-synuclein-reactive band was observed in P fraction (insoluble protein fraction) of PD cases but was absent in control cases. D) Fractionation efficiency was verified by mouse mAb against Annexin II. Annexin II marker for membranes and early endosomes was detected in S2, but neither S1 nor P fractions, demonstrating high efficacy of separation of the 3 fractions. Numbers beneath PVDF membranes correspond to C and PD cases identified in Table 1 . Table 1 . In fractions of both control and PD midbrain, the isodipeptide mAb detected high concentrations of a 52 kDa crosslinked protein described previously (14) . In the S1 fraction, additional faint bands at ~36 kDa were eluted from both control and PD tissue. In the S2 fraction, additional bands of ~16, 32, and 45 kDa were detected, which were more prominent in PD than in control samples. In P fraction, the only additional band detected eluted at ~45 kDa, and it was stronger in PD than in control cases. It is important to note that this membrane was cut below the level of the stacking gel, which explains the absence of very high molecular mass proteins previously detected. We propose that tTG-catalyzed intramolecular crosslinking of cytoplasmic α-synuclein is an early event in PD pathogenesis that leads to impaired function, inducing disturbances in vesicle recycling and receptor endocytosis. The isodipeptide crosslink is a covalent bond, which can only be broken catalytically; hence, there is an equilibrium shift toward the crosslinked species. Crosslinked α-synuclein also acts as a nucleation site, seeding aggregation and leading to saturation of protein degradation systems.
